Pressmeddelande -
Xbrane Bioscience and DNA2.0 initiate marketing collaboration
Xbrane Bioscience’s Rhamex™ Protein Expression System Becomes First Set of Vector Constructs Available Through Gene Designer—DNA2.0’s Gene Assembly and Design Application
BOSTON, PEGS Summit, 9th of May, 2011—Xbrane Bioscience and DNA2.0 today announced that they enter into a collaboration to market Xbrane Bioscience’s innovative protein expression system; Xbrane Rhamex™ System through DNA 2.0’s groundbreaking gene assembly and design application, Gene Designer. The Rhamex™ protein expression systems from Xbrane Bioscience will be the first commercial constructs that users will be able to access and order directly through Gene Designer.
Xbrane’s bacterial protein expression system is tightly controlled and enables high expression yields, even of toxic and otherwise challenging proteins in any E. coli strain. Xbrane’s Rhamex™ system is tightly regulated at the individual cell level but at the same time capable of producing high protein yields and facilitate production of more bioactive and correctly folded proteins per production run.
“While research scientists and production technologists are often limited in their choice of bacterial expression systems for the production of toxic proteins, we are excited to partner with DNA2.0 to offer our affordable, user-friendly Rhamex expression systems through Gene Designer,” said Lykke Abdon Director of Marketing of Xbrane Bioscience. “We are entering a new age of bioengineering that relies on the availability of the kind of preassembled, specialized DNA building blocks that Xbrane makes, and DNA2.0’s Gene Designer offers an exceptional marketplace for sharing, designing and constructing novel genetic constructs.”
We’re creating a marketplace for synthetic biology, with Gene Designer serving as the “app store” for molecular biologists,” said Dr. Claes Gustafsson, Chief Operating Officer at DNA2.0. “Not only does Gene Designer offer a powerful design application with rich graphics and a patented drag-and-drop functionality, but now users will have access to license powerful preassembled and validated constructs such as Xbrane’s expression system, fundamentally streamlining the process of creating and purchasing genes.”
Ämnen
- Farmaci
Kategorier
- bioteknik
- membranproteiner
- protein-läkemedel
- proteinbaserade läkemedel
- proteinforskning
- proteinproduktion
- xbrane
- xbrane bioscience
- biologiska läkemedel
- rhamex
- dna2.0
- genforskning
About Xbrane Bioscience
Xbrane Bioscience develops and commercializes platforms for the efficient and cost-effective production of proteins and vaccines. The company was founded early 2008, as a spin-off company from the world-leading Center for Biomembrane Research at the Department of Biochemistry & Biophysics of Stockholm University, Sweden. The company has developed and sells two bacterial based protein expression systems providing unprecedented versatility, Xbrane Lemo System™ and Xbrane Rhamex System™. Xbrane Bioscience is currently further expanding its portfolio of innovative technologies, including platforms for the development of multivalent vaccines and the efficient production of toxic and unstable proteins. For more information about Xbrane Bioscience visit www.xbrane.com.
About DNA2.0
Founded in 2003, DNA2.0 is the leading gene synthesis and protein engineering company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 has provided genes to thousands of customers, for whom it has synthesized many millions of base pairs. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com or email Claes Gustafsson, COO: cgustafsson@DNA20.com.